Gaining Ground on Neurodegenerative Diseases

Show Floor, Sky Stage

October 8, 2023

Dr. Marc Haut

Rockefeller Neuroscience Institute

Elli Kaplan

Neurotrack

Jamie Eberling

The Michael J. Fox Foundation

Mark Mintun

Eli Lilly and Company

Julie Wroblewski

Magnify Ventures

HTLH sessions summaries are sponsored by Abridge, the leader in real-time generative AI for clinical documentation. For a demo of the Abridge solution - used by thousands of clinicians everyday - see us at booth 5923. Video summaries are generated by a third party

This panel discussed the rising prevalence of neurodegenerative diseases, including Alzheimer's and Parkinson's, and the importance of breakthroughs in treatment and care for these diseases. The discussion highlighted the advances in biomarker development and the significance of early detection and diagnosis. They discussed the recent validation of the first test that can detect Parkinson's disease and potential game-changing advancements like blood tests and technology in early diagnosis and treatment. The development of a drug capable of slowing the progression of Alzheimer's by Eli Lilly and Company was also discussed, along with advances in brain health programs aimed at preventing the onset of such diseases. The panelists underscored the urgency to increase funding and policy changes to support research, develop better biomarkers, and enhance access to treatments.

The HLTH team is processing the video. Your summary will be ready soon. Check back later.